One To Watch

Protagonist Therapeutics

A clinical-stage biopharmaceutical company leveraging proprietary peptide technology to develop therapeutics for inflammation, hematology, and metabolic diseases, with multiple late-stage programs including rusfertide for polycythemia vera.

Company Overview

Protagonist Therapeutics is a publicly traded biopharmaceutical company focused on discovering and developing peptide-based therapeutics targeting areas of significant unmet medical need across rare and prevalent diseases. Based in Milpitas, California, the company operates a differentiated platform enabling the discovery of highly potent, selective, and optimized peptide candidates. As of March 2026, Protagonist trades under the ticker PTGX on NASDAQ with a market capitalization of approximately 6.2 billion dollars and 63.8 million shares outstanding, reflecting investor confidence in its clinical pipeline and strategic partnerships. The company employs a disciplined approach to drug development, combining internal discovery capabilities with strategic collaborations to maximize pipeline potential and accelerate time to market for patients in need.

Headquarters and Global Presence

Protagonist Therapeutics maintains its corporate headquarters in Milpitas, California, where the majority of its research, development, and administrative functions are based. The company initially established a U.S. presence with offices in Redwood City in 2009, which served as the foundation for building operational infrastructure in the United States market. Beyond its primary California location, Protagonist operates additional offices and research facilities to support its global development programs. The company's geographic focus is primarily on the United States market, though its partnerships with international pharmaceutical companies, particularly Janssen and Takeda, extend its reach and development networks across multiple regions, ensuring coordinated development strategies for its investigational medicines.

Founding and History

Protagonist Therapeutics was founded in 2006, built upon proprietary technology originally developed at the University of Pennsylvania. The company was conceived and incubated at the Institute for Molecular Sciences in Australia before establishing its U.S. corporate operations. Dr. Dinesh Patel, who continues to serve as President and Chief Executive Officer, founded the company in December 2008 and has provided consistent strategic leadership throughout its growth trajectory. Mark Smythe, a key co-founder, contributed the Vectrix scaffold technology platform that underpins the company's peptide discovery capabilities. In 2016, Protagonist completed its initial public offering, moving from a private biotech company to a publicly traded entity and enabling significant capital deployment toward clinical development. This transition marked a pivotal moment in the company's history, positioning it to pursue more ambitious therapeutic programs and establish transformative strategic partnerships with major pharmaceutical companies.

Therapy Areas and Focus

Protagonist Therapeutics strategically concentrates its efforts on three therapeutic areas with significant market opportunities and unmet patient needs: inflammation and immunology, hematology, and metabolic diseases. In inflammation and immunology, the company focuses on inflammatory bowel disease and psoriasis, leveraging its oral peptide platform to develop more convenient treatment options than existing therapies. The hematology focus centers on blood disorders, particularly polycythemia vera, a myeloproliferative neoplasm where traditional phlebotomy remains the standard of care and novel approaches are desperately needed. The metabolic diseases vertical targets obesity and related conditions, reflecting the growing pharmaceutical investment in this area and patient demand for effective treatments. This three-pronged therapeutic approach diversifies risk while capitalizing on Protagonist's peptide platform strengths, which are particularly well-suited to creating oral and injectable therapies with favorable pharmacokinetic properties, potency, and selectivity profiles that differentiate candidates in crowded therapeutic markets.

Technology Platforms and Modalities

Protagonist's proprietary Vectrix technology platform represents a breakthrough in constrained peptide design, enabling the discovery of peptides with optimized potency, specificity, selectivity, solubility, metabolic stability, and manufacturability. The platform incorporates advanced molecular design tools and virtual libraries of conformationally constrained scaffolds, allowing the company to rapidly explore chemical space and identify lead candidates with ideal drug-like properties. Vectrix enables Protagonist to engineer peptides that overcome traditional limitations of peptide therapeutics, including poor bioavailability and rapid degradation, through sophisticated peptidomimetic and chemical modifications. The platform supports discovery of candidates targeting diverse biological mechanisms, from G-protein coupled receptors and ion channels to cytokine signaling pathways. Protagonist's technology expertise spans both oral and injectable delivery formats, providing flexibility in development approaches and enabling optimization for specific therapeutic indications. This platform-driven approach significantly reduces discovery timelines, improves clinical success rates, and provides a competitive moat that is difficult for competitors to replicate, positioning Protagonist advantageously in a peptide therapeutics landscape increasingly dominated by larger pharmaceutical companies.

Key Pipeline and Programs

Rusfertide (PTG-300), Protagonist's lead program, is an injectable hepcidin mimetic in Phase III development for polycythemia vera. In the pivotal VERIFY Phase III trial, 61.9 percent of patients continuously treated with rusfertide maintained absence of phlebotomy eligibility, with 77.9 percent of placebo crossover patients achieving this response. Long-term data presented at ASH 2025 demonstrated durable hematocrit control with a greater than 13-fold reduction in estimated annual therapeutic phlebotomy rate compared to baseline, positioning rusfertide as potentially transformative for patients with this serious blood disorder. An NDA was submitted to the FDA, with Protagonist exercising its right to opt out of the Takeda profit-sharing arrangement in the U.S. during the second quarter of 2026, establishing full U.S. commercialization rights. JNJ-2113 (PN-235), partnered with Janssen, is an oral interleukin-23 receptor antagonist in Phase II/III development for inflammatory bowel disease and psoriasis. Icotrokinra, another oral IL-23R antagonist, advances in separate indications with Phase III data presented at the American Academy of Dermatology 2026 annual meeting showing one-year efficacy in moderate-to-severe plaque psoriasis. The pre-clinical pipeline was recently expanded with novel wholly-owned candidates including PN-477, an oral and subcutaneous triple GLP-GIP-GCG agonist; PN-458, a dual GLP-GIP agonist; and PN-8047, an oral hepcidin functional mimetic targeting metabolic disease indications, with PN-881 Phase I studies expected to conclude by mid-2026.

Key Personnel

Dr. Dinesh Patel serves as President and Chief Executive Officer, bringing 38 years of executive, entrepreneurial, and scientific experience across pharmaceutical, biotechnology, and biopharmaceutical industries. He has provided strategic leadership since the company's founding in 2008. Dr. Harold E. Selick chairs the Board of Directors, leveraging prior experience as Chief Executive Officer of Threshold Pharmaceuticals to provide governance and strategic oversight. The executive team includes Asif Ali as Chief Financial Officer (since 2022), overseeing financial strategy and capital management; Dr. Arturo Molina as Chief Medical Officer (since 2022), directing clinical development strategy; Dr. Rajesh Bhandari as Executive Vice President and Chief Discovery Officer (since January 2022), leading drug discovery and platform advancement; Mohammad Masjedizadeh as Chief Technical Officer and Executive Vice President (since 2021), managing manufacturing, scale-up, and technical operations; and Dr. Ravi Gupta as Executive Vice President of Clinical Development (since 2019), overseeing clinical trial execution and regulatory interactions. This experienced leadership team combines deep biotech expertise with proven track records in advancing molecules through clinical development and commercialization.

Strategic Partnerships

Janssen Biotech, a Johnson & Johnson company, entered a worldwide exclusive license and collaboration agreement with Protagonist for JNJ-2113, an oral IL-23R antagonist for inflammatory bowel disease. Under the agreement, Protagonist is eligible for up to 855 million dollars in development and commercialization milestone payments plus tiered royalties on worldwide net drug sales, with co-detailing rights in the U.S. Johnson & Johnson maintains exclusive worldwide rights to develop and commercialize compounds derived from collaborative research against a broad range of indications. This partnership reflects a long-standing relationship fostered through equity investments by JJDC, Inc., establishing Protagonist as a valued innovation partner. Takeda Pharmaceutical partnered with Protagonist for rusfertide development, providing co-development and commercialization support with a 50-50 profit and loss sharing arrangement in the U.S., which Protagonist may opt out of as outlined above. As of March 2026, Johnson & Johnson is reported to be in discussions to acquire Protagonist Therapeutics, a transaction that would enhance the collaboration and provide Protagonist access to J&J's global development and commercialization infrastructure. These partnerships validate Protagonist's technology platform and pipeline while providing meaningful financial support and accelerating development timelines for key programs.

FAQ Section

Protagonist Therapeutics has developed the Vectrix technology platform, a proprietary system for discovering conformationally constrained peptides with optimized potency, specificity, selectivity, solubility, metabolic stability, and manufacturability. Originally developed by co-founder Mark Smythe based on technology from the University of Pennsylvania, Vectrix incorporates advanced molecular design tools and virtual libraries of constrained peptide scaffolds. The platform enables the company to apply sophisticated peptidomimetic and chemical modifications to create oral and injectable peptide therapeutics that overcome traditional limitations of peptide drugs, such as poor bioavailability and rapid degradation. This differentiated approach allows Protagonist to discover candidates rapidly across diverse biological targets and therapeutic indications, providing a significant competitive advantage in the peptide therapeutics landscape and supporting its portfolio of clinical programs.

Rusfertide (PTG-300) is an injectable hepcidin mimetic peptide in Phase III development for polycythemia vera, a myeloproliferative neoplasm characterized by excessive red blood cell production. Hepcidin is a key iron-regulatory hormone, and rusfertide mimics its function to reduce iron availability and suppress abnormal red blood cell production, thereby controlling hematocrit levels without requiring regular phlebotomy. In the pivotal VERIFY Phase III trial, rusfertide demonstrated that 61.9 percent of continuously treated patients maintained absence of phlebotomy eligibility, compared to 77.9 percent of placebo crossover patients achieving this response. Long-term data presented at the American Society of Hematology 2025 conference showed durable hematocrit control with greater than 13-fold reduction in estimated annual therapeutic phlebotomy compared to baseline. An NDA was submitted to the FDA, and Protagonist exercised its opt-out right in the U.S. in the second quarter of 2026, establishing full commercial control. This approval would represent Protagonist's first marketed product and potentially the first non-phlebotomy-based treatment for polycythemia vera.

JNJ-2113 (formerly PN-235) is an oral interleukin-23 receptor antagonist developed through Protagonist's partnership with Janssen Biotech, a Johnson & Johnson company. IL-23 is a key inflammatory cytokine involved in multiple immune-mediated diseases, and JNJ-2113 is designed to selectively block the IL-23 signaling pathway. The program is being developed across multiple indications, with primary focus on inflammatory bowel disease including Crohn's disease and ulcerative colitis, where it is in Phase II/III clinical development. Additionally, JNJ-2113 is advancing in psoriasis, a chronic inflammatory skin condition affecting millions of patients worldwide. The partnership grants Janssen worldwide exclusive rights to develop and commercialize JNJ-2113, with Protagonist eligible for up to 855 million dollars in milestone payments plus tiered royalties on worldwide net drug sales. Protagonist retains co-detailing rights in the U.S., allowing participation in the commercial launch. Success with JNJ-2113 across these indications would validate Protagonist's peptide platform and establish the company as a meaningful player in immunology therapeutics.

Protagonist's proprietary Vectrix platform enables the design of oral and injectable peptide therapeutics with characteristics that overcome historical limitations of peptide drugs. Traditional peptides suffer from poor oral bioavailability due to degradation in the gastrointestinal tract, requiring frequent injections or infusions to maintain therapeutic levels. Protagonist's approach utilizes conformationally constrained scaffolds and advanced chemical modifications to enhance metabolic stability, solubility, and cellular absorption. This engineering allows candidates like JNJ-2113 (an oral IL-23R antagonist) to achieve acceptable bioavailability when administered orally, providing significant convenience advantages over injectable alternatives. The ability to develop both oral and injectable formats from the same platform provides flexibility in development strategy and optimization for specific indications based on clinical need and patient preference. This technological advancement positions Protagonist's peptides to compete more effectively with small-molecule drugs and monoclonal antibodies in therapeutic categories where oral administration is highly valued, such as inflammatory bowel disease and psoriasis. The differentiation is particularly important for chronic diseases requiring long-term therapy where patient convenience and adherence significantly impact outcomes.

Protagonist's partnership with Johnson & Johnson, structured through Janssen Biotech, represents a transformational validation of the company's peptide platform and development capabilities. Under the agreement for JNJ-2113, Janssen secured worldwide exclusive rights to develop and commercialize the oral IL-23R antagonist across a broad range of indications, reflecting confidence in both the molecule and Protagonist's discovery capabilities. Protagonist is eligible to receive up to 855 million dollars in development and commercialization milestone payments, providing substantial non-dilutive funding to support pipeline advancement and operations. Additionally, the company receives tiered royalties on worldwide net drug sales and retains the right to co-detail in the U.S. market, enabling participation in commercial success. The partnership emerged from a long-standing relationship built through multiple equity investments by JJDC, Inc., J&J's corporate venture arm, demonstrating sustained confidence in Protagonist's technology. As of March 2026, Johnson & Johnson is reported to be in active discussions to acquire Protagonist Therapeutics, suggesting potential consolidation that would integrate the company's platform and pipeline into J&J's global development and commercialization infrastructure. This transaction would provide Protagonist shareholders significant liquidity and provide the company access to resources required for large-scale clinical development and commercial launch of multiple programs simultaneously.

In response to the significant commercial opportunity in metabolic diseases, particularly obesity and weight management, Protagonist has expanded its wholly-owned pre-clinical pipeline with novel candidates targeting this therapeutic area. PN-477 is an oral and subcutaneous triple GLP-GIP-GCG receptor agonist designed to provide multi-pathway activation of metabolically important receptors, potentially offering enhanced efficacy compared to dual or single-pathway approaches. GLP-1 receptor agonists have demonstrated significant weight loss effects, and combining GLP-1 signaling with GIP and GCG receptor activation may provide synergistic benefits or improved side effect profiles. PN-458 is a dual GLP-GIP agonist, also available in oral and subcutaneous formats, providing a simpler option if dual activation proves sufficient for clinical benefit. PN-8047 is an oral hepcidin functional mimetic targeting metabolic disease indications, reflecting the company's expertise in hepcidin biology beyond its application in polycythemia vera. The company expects Phase I studies of PN-881 to conclude by mid-2026, advancing the discovery pipeline. These programs position Protagonist to capture an increasingly important segment of pharmaceutical development, where market demand and pricing support significant value creation, and where the company's peptide platform provides advantages in oral bioavailability, potency, and potential combination capability.

Polycythemia vera is a myeloproliferative neoplasm affecting approximately 10,000 to 25,000 patients in the United States, characterized by uncontrolled proliferation of red blood cells resulting in elevated hematocrit levels, blood viscosity, and significantly increased risk of thrombotic events and hemorrhage. The current standard of care relies on phlebotomy, a procedure requiring patients to undergo regular blood removal to maintain hematocrit below target levels, typically requiring 8 to 12 procedures annually. This approach is burdensome for patients, creating significant quality-of-life impact and healthcare utilization costs. Existing pharmacological treatments including cytoreductive agents have significant toxicity and side effect profiles. Rusfertide addresses this unmet need by mimicking hepcidin, the primary physiological regulator of iron availability, thereby suppressing erythropoiesis (red blood cell production) without direct cytotoxic effects. Clinical data from the VERIFY trial demonstrated that rusfertide reduced phlebotomy requirements by greater than 13-fold compared to baseline, with long-term durability demonstrating sustained hematocrit control. If approved by the FDA in 2026, rusfertide would represent the first meaningful non-phlebotomy-based treatment option and would address a significant treatment gap. The market for improved polycythemia vera treatments is substantial, with willingness-to-pay high given the chronic nature of disease and burden of current management, supporting commercial potential and justifying Protagonist's decision to exercise its opt-out right and pursue U.S. commercialization independently.

Want to Update your Company's Profile?